The conjugate vaccines denotes to those
vaccines which consist bacterial capsule polysaccharide or the antigen
committed or conjugated to a protein. Such protein has a foremost role in
developing the immunogenic feature of the polysaccharide. The conjugate
vaccines are majorly utilized to vaccinate infants and children against the
aggressive disease caused by the Hib bacteria, H. inflenzae, Neisseria
meningitides, and streptococcus pneumoniae. The effective augment in the usage
of conjugate vaccines for adults, increase in the number of the regulatory
endorsements for the conjugate vaccines, increment in the prevalence of the
diseases caused by the microorganisms namely Neisseria meningitides and
streptococcus pneumoniae, and the advanced developments in the technology fuel
the growth of the market during the short span of time.
The market for conjugate vaccines is
anticipated to grow, due to the global awareness about the advantages of the
vaccination for the anticipation of certain life-threatening diseases, mounting
the initiatives for production of low-cost vaccines, and widespread monotonous
vaccination programmes in underdeveloped economies. The market will witness a
stable growth, increasing at a compound annual growth rate (CAGR) of 11.7%
during reviewed period of 2017-2022, to reach approximately USD 87.7 Bn by
2022.
According to the report analysis, ‘Global
Conjugate Vaccines Market (2017 - 2022)’ states that in the global
conjugate vaccines market, there are numerous key players which presently functioning
for leading the fastest market growth and dominating the handsome value of
market share around the globe during the short span of time while developing
the technologies, delivering the better consumer satisfaction, decreasing the
price of the services and spreading the awareness related to the benefits of
the vaccines includes GlaxoSmithKline, Pfizer Inc., Merck & Co., Novartis,
Sanofi Pasteur, CSL Limited, Bharat Biotech International, Biological E
Limited, Serum Institute of India and several others.
Not only has this, many of the large
corporates in the global conjugate vaccine market are adopting the strategies
to enlarge the business premises and investing the high amount of money for
developing the services at a reasonable price and generating the high amount of
money.
Based on the end user, the adult sector
dominated the higher market share than the paediatric sector owing to an
effective increase in the awareness on conjugate vaccines for adults, over the
years. Still, the saturation level for adult conjugate vaccines is
comparatively low, with the lowest being for PCVs. Hence, the growth
prospective is very high. The paediatric vaccines, on the other hand is a
steady market and be contingent extremely on the birth rates in each economy.
The vaccination programmes, specially taken up by global organizations such as
the United Nations Educational, Scientific and Cultural Organization (UNESCO),
have been efficacious in eliminating several such vaccine-preventable diseases.
The Asia-Pacific region is the principal
market for conjugate vaccines, which controlled a share of 42%, in 2017. The
principal indicators of the probable for the vaccine market is the geriatric
populace in the county, particularly in realms such as India and China. In
turn, this has, invigorated market participants to augment the spending on
research and development (R&D) and distribution facilities in these region.
North America is the second principal market for conjugate vaccines, due to the
country’s widespread immunization programmes. Therefore, in the coming years,
it is anticipated that the market of conjugate vaccines will increase around
the globe more positively over the coming years.
For more information, click on the
link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing &
Communications
+91
9015378249